Search

Displaying results 6721 - 6730 of 7379 in total
  1. Drug

    R-348

    go.drugbank.com/drugs/DB06321
    Investigational

    Synonyms: 5-Fluoro-N-(4-methyl-3-propionylaminosulfonylphenyl)-N'-(4-(prop-2-ynyloxy)phenyl)-2,4-pyrimidinediamine
  2. Drug

    CRx-139

    go.drugbank.com/drugs/DB05744
    Experimental

    It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects.

  3. Drug

    SVV-001

    go.drugbank.com/drugs/DB06129
    Investigational

    SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional chemotherapeutics with no overt toxicity at doses one million times higher than effective doses in

  4. Drug

    Cirazoline

    go.drugbank.com/drugs/DB09202
    Experimental

    Cirazoline has also been shown to decrease food intake in rats, purportedly through activation of α1-adrenoceptors in the paraventricular nucleus in the hypothalamus of the brain.

  5. Drug

    Lotiglipron

    go.drugbank.com/drugs/DB21631
    Investigational

    Lotiglipron is under investigation in clinical trial NCT05579977 (Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People

  6. Drug

    Befunolol

    go.drugbank.com/drugs/DB09013
    Experimental

    Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.

  7. Drug

    MaxAdFVIII

    go.drugbank.com/drugs/DB17713
    Experimental

    First developed by GenStar, it is being investigated for the treatment of hemophilia.

  8. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.

  9. Drug

    Eritoran

    go.drugbank.com/drugs/DB04933
    Investigational

    It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.

  10. Drug

    Dipropyl-4-hydroxytryptamine

    go.drugbank.com/drugs/DB13990
    Experimental

    Dipropyl-4-hydroxytryptamine was first synthesized by Alexander Shulgin. This agent and its properties haven't been fully elucidated.

    Synonyms: 4-HO-DPT, 4-Hydroxy-N,N-dipropyltryptamine